JACC:△CHA2DS2-VASc能更好地预测房颤患者卒中发生的风险

2018-01-12 MedSci MedSci原创

目前,评估房颤患者缺血性卒中发生风险主要是通过CHA2DS2-VASc评分系统,而结局预后则是在随访一定时间后进行评估。然而这种评分系统有一个弊端,即房颤患者发生卒中的风险并不是静止不变的,在随访期间可能会发生变化。本研究的目的旨在利用新型的△CHA2DS2-VASc评分系统来反映房颤患者随访期间卒中风险发生的变化。本研究纳入了31039名没有接受抗血小板治疗的房颤患者,并且除了年龄和性别外无CH

目前,评估房颤患者缺血性卒中发生风险主要是通过CHA2DS2-VASc评分系统,而结局预后则是在随访一定时间后进行评估。然而这种评分系统有一个弊端,即房颤患者发生卒中的风险并不是静止不变的,在随访期间可能会发生变化。

本研究的目的旨在利用新型的△CHA2DS2-VASc评分系统来反映房颤患者随访期间卒中风险发生的变化。

本研究纳入了31039名没有接受抗血小板治疗的房颤患者,并且除了年龄和性别外无CHA2DS2-VASc评分系统中的并发症。△CHA2DS2-VASc评分则是指患者基线和随访期间CHA2DS2-VASc评分的差值。经过171956人年后,有4103名患者发生了缺血性卒中事件,研究者将基线CHA2DS2-VASc评分、随访后CHA2DS2-VASc评分和△CHA2DS2-VASc评分分别与患者预后进行相关性分析,并进行相互间比较。结果发现,患者基线的平均CHA2DS2-VASc评分为1.29,随访期间增加至2.31,平均△CHA2DS2-VASc评分为1.02。CHA2DS2-VASc评分仅在40.8%的患者中保持不变。在4103名发生缺血性卒中患者中,有89.4%的患者△CHA2DS2-VASc评分≥1,而无卒中患者中仅有54.6%△CHA2DS2-VASc评分≥1。△CHA2DS2-VASc评分在预测房颤患者缺血性卒中发生风险方面要优于基线和随访期间CHA2DS2-VASc评分。

研究结果显示,房颤患者发生缺血性卒中的风险并不是一成不变的,患者基线和随访期间CHA2DS2-VASc评分的差值(△CHA2DS2-VASc)能更好的预测患者卒中的发生风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782917, encodeId=479d1e82917bc, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Sep 16 03:48:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938781, encodeId=ae011938e8153, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Apr 24 10:48:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853903, encodeId=f758185390302, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Nov 18 18:48:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325667, encodeId=53f4132566ed1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573493, encodeId=6b8115e349397, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614429, encodeId=bf3416144292a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=)]
    2018-09-16 huperzia
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782917, encodeId=479d1e82917bc, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Sep 16 03:48:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938781, encodeId=ae011938e8153, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Apr 24 10:48:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853903, encodeId=f758185390302, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Nov 18 18:48:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325667, encodeId=53f4132566ed1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573493, encodeId=6b8115e349397, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614429, encodeId=bf3416144292a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=)]
    2018-04-24 仁者大医
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782917, encodeId=479d1e82917bc, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Sep 16 03:48:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938781, encodeId=ae011938e8153, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Apr 24 10:48:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853903, encodeId=f758185390302, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Nov 18 18:48:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325667, encodeId=53f4132566ed1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573493, encodeId=6b8115e349397, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614429, encodeId=bf3416144292a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=)]
    2018-11-18 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782917, encodeId=479d1e82917bc, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Sep 16 03:48:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938781, encodeId=ae011938e8153, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Apr 24 10:48:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853903, encodeId=f758185390302, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Nov 18 18:48:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325667, encodeId=53f4132566ed1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573493, encodeId=6b8115e349397, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614429, encodeId=bf3416144292a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1782917, encodeId=479d1e82917bc, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Sep 16 03:48:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938781, encodeId=ae011938e8153, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Apr 24 10:48:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853903, encodeId=f758185390302, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Nov 18 18:48:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325667, encodeId=53f4132566ed1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573493, encodeId=6b8115e349397, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614429, encodeId=bf3416144292a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1782917, encodeId=479d1e82917bc, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Sep 16 03:48:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938781, encodeId=ae011938e8153, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Apr 24 10:48:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853903, encodeId=f758185390302, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Nov 18 18:48:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325667, encodeId=53f4132566ed1, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573493, encodeId=6b8115e349397, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614429, encodeId=bf3416144292a, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Sun Jan 14 00:48:00 CST 2018, time=2018-01-14, status=1, ipAttribution=)]

相关资讯

JAHA:妊娠期高血压患者子代出现心血管代谢异常的风险更高!

目前,对于妊娠期高血压(HDP)患者子代成年后的心血管代谢健康状况尚属未知。本研究目的旨在评估HDP患者子代成年后视网膜微血管和心脏的结构变化。本研究纳入了1006名孕期≥37周出生的子代,并在其成年期对视网膜微血管和心脏结构进行评估,评估时的平均年龄为40岁(34-49岁)。结果发现,与正常妊娠的子代相比,妊娠期高血压子代的收缩压更高(β=4.68, P<0.001),体重指数更高(β=1

JAHA:国内学者揭示PM2.5引起高血压的新机制

流行病调查显示,空气污染与高血压的发生相关联,但是其具体机制尚未阐明。本研究发现,长期暴露于细颗粒物(PM2.5)能导致高血压和损伤肾脏对钠的排泄,这可能是由于较低的D1受体的表达和更高的D1受体的磷酸化,伴随着较高的G蛋白偶联受体激酶4(GRK4)的表达。D1受体表达和功能的下调可能是由于肾脏近曲小管细胞暴露于PM2.5后导致GRK4的表达升高。由于活性氧在D1受体功能紊乱及其与大气污染之间起到

Eur Heart J:β受体阻滞剂能改善心衰伴LVEF降低患者的预后

近期,指南推荐心衰伴左室射学分数(LVEF)40%-49%患者的管理方法应与LVEF≥50%的患者一样。本研究目的旨在通过分析回顾随机双盲安慰剂对照临床试验评估β受体阻滞剂在不同LVEF人群中的作用。本研究对11个临床试验进行荟萃分析,并通过基线的LVEF和心律水平进行分层。主要终点事件是1.3年随访事件后的全因死亡率和心血管死亡。在14262名窦性心律的个体中,平均LVEF是27%,包括575名

Diabetes Care:2型糖尿病患者严重低血糖事件与心血管结局风险之间的相关性分析!

这些结果表明心血管事件发生后SHEs风险更大,以及SHEs发生后心血管事件风险增加。

JCEM:糖尿病患者心血管住院和再住院风险评分!

由此可见,该研究已经开发并通过外部验证了两个新的预测心血管疾病住院和再住院风险的预测模型。它们是基于在许多发达国家初级保健机构中为2型糖尿病患者提供的少量临床测量结果,并且其可以作为筛查心血管疾病住院和再住院高风险人群的工具。

临床心得:初判胸痛原因 这样做才准

对于心血管科医生来说,胸痛患者是最大的一个症候群,而胸痛的鉴别诊断几乎是我们的日常工作。但是,胸痛的原因非常复杂,涉及的疾病种类繁多,真正典型的缺血性胸痛并不常见,甚至有些看似典型的缺血性胸痛症状中隐藏着陷阱,对临床医师的判断造成干扰。